Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

qPCR Microfluidics point-of-care platform for dengue diagnosis

Project description

A fast assay for the diagnosis of vector-borne diseases

The diseases caused by the Dengue, Zika and Chikungunya viruses are transmitted to humans through the female Aedes mosquito. Similarities in symptoms make differential diagnosis impossible, impeding appropriate and timely medical intervention. To address this problem, scientists of the EU-funded DENVPOC project will develop a fast multiplex PCR assay for discriminating between the different viruses. The PCR assay requires only a small human sample and can be combined with automatic sample pre-processing and a microfluidics system to reduce time and cost. More importantly, it will assist in the rapid screening of pregnant women and people living in or travelling through/from outbreak areas.

Objective

As a result of Global climate change and fast urbanization, global outbreaks of Dengue (DENV)/ Zika(ZIKV)/Chikungunya(CHIKV) virus have the potential to occur. The most common pathway of these infections in humans is through the female Aedes mosquito vector. DENV is an exanthematous febrile disease with varied clinical manifestations and progressions . Due to similarities in symptoms between DENV and ZIKV and CHIKV, it is difficult to make a differential diagnosis, impeding appropriate, timely medical intervention. Furthermore, cross-reactivity with ZIKV, which was recently related to microcephaly, is a serious issue. In 2016, in Brazil alone, there were 4180 microcephaly cases reported instead of 163 cases, more in line with yearly expected projections , , Thus, the sooner an accurate diagnostic which differentiates DENV from the other manifestations is critical; most especially at the early stages of the infection, to have a reliable diagnosis in pregnant women. In 2016, the OMS emergency committee declared that the outbreaks and the potentially resultant neurological disorders in Brazil were an important international state of emergency in public health, as a result of the associated secondary effects; these diseases became a Global concern. This project allows developing a highly and fast Multiplex qPCR POC platform by using FASTGENE technology with a minimal amount of patient serotype. It would reduce the time of analysis (30 to 90’ for a standard) and costs. Additionally, the sample preprocessing and thermalization will shorten real-time PCR amplification time and will be integrated within the microfluidic systems. This platform can result in a commercialized product whereupon a main market target would be pregnant women and people living or traveling through/from outbreak risk areas.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

BFORCURE
Net EU contribution
€ 196 707,84
Address
14 RUE DE LA BEAUNE
93100 MONTREUIL
France
SME
Yes
Region
Ile-de-France Ile-de-France Seine-Saint-Denis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 196 707,84